Jian Hou

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Jie Xu, Lijuan Chen, Shuangshuang Yang et al. · Proceedings of the National Academy of Sciences · 2019 · 399 citations · Full text

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios Α. Dimopoulos, Jens Hillengaß, Saad Z. Usmani et al. · Journal of Clinical Oncology · 2015 · 387 citations · Full text

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

Lu Jiang, Zhaohui Gu, Zi‐Xun Yan et al. · Nature Genetics · 2015 · 372 citations

Lymphoid Neoplasia, Natural Killer/t-cell Lymphoma, Somatic Variant +8

Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

Hua Jiang, Wenhao Zhang, Peipei Shang et al. · Molecular Oncology · 2013 · 263 citations · Full text